McKesson posts 18% YoY growth in US pharmaceuticals as stock hovers near all time highs
AInvestWednesday, Feb 7, 2024 10:21 pm ET
1min read
MCK --

McKesson Corporation (MCK), a leading healthcare services and information technology company, reported its Q3 earnings for the fiscal year 2024. The company's revenue increased by 15% YoY to $80.9 billion, beating analysts' estimates of $77.86 billion. This growth was primarily driven by increased prescription volumes, including higher volumes from specialty products, retail national account customers, and GLP-1 medications. 

The US Pharmaceutical segment, which accounts for most the company's revenue, saw a 18% increase YoY to $73.02 billion. This growth was driven by increased prescription volumes, including higher volumes from specialty products, retail national account customers, and GLP-1 medications. The segment's operating profit was $307 million, while adjusted operating profit was $828 million, an increase of 6% YoY.

The Prescription Technology Solutions segment reported revenue of $1.21 billion, a 7% increase YoY, driven by increased prescription volumes in the technology services and third-party logistics businesses. The segment's operating profit was $178 million, while adjusted operating profit was $193 million, an increase of 25% YoY. 

The Medical-Surgical Solutions segment reported revenue of $3.03 billion, a 1.5% increase YoY, driven by growth in the primary and extended care businesses, partially offset by lower contribution from kitting, storage, and distribution of ancillary supplies for the US government's COVID-19 vaccine program. The segment's operating profit was $268 million, while adjusted operating profit was $282 million, a decrease of 16% YoY. 

The International segment reported revenue of $3.64 billion, a 18% decrease YoY, driven by divestitures within McKesson's European business, partially offset by higher pharmaceutical distribution volumes in the Canadian business. The segment's operating profit was $126 million, while adjusted operating profit was $104 million, a decrease of 27 % YoY, driven by divestitures within McKesson's European business. 

The company raised and narrowed its guidance range for fiscal 2024 adjusted earnings per diluted share to $27.25 to $27.65. 

In conclusion, McKesson's Q3 earnings report highlights the company's strong performance in the US Pharmaceutical segment, driven by increased prescription volumes and higher sales of specialty products, GLP-1 medications, and retail national account customers. The company's adjusted earnings per diluted share of $7.74 increased by 12% YoY, beating analysts' estimates of $7.04. The company's adjusted EPS guidance for fiscal 2024 has been raised to $27.25 to $27.65. 


Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.